Publications by authors named "Jan Lycke"

Claim this Profile
T
The relationship between CSF/serum immunoglobulin and albumin ratio across laboratories: a retrospective, multi-center study.
Harald Hegen, Ulf Andreasson, Juan J Archelos-Garcia, Gerhard Bachmaier, Kaj Blennow, Jan Lycke

Fluids Barriers CNS· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphocyte Dynamics and the Emergence of Secondary Autoimmunity Following Immune Reconstitution Therapies in Multiple Sclerosis.
Sofia Sandgren, Lenka Novakova, Markus Axelsson, Igal Rosenstein, Jan Nils Lycke

Neurol Neuroimmunol Neuroinflamm· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing progression independent of relapse activity.
Sofia Sandgren, Aleksandra Maleska Maceski, Pascal Benkert, Maximilian Einsiedler, Sabine Schaedelin, Jan Lycke

Mult Scler· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook.
Luisa Klotz, Thomas Berger, Wallace J Brownlee, Andrew Chan, Jan Lycke

Ther Adv Neurol Disord· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome.
Nicolás Fissolo, Sabine Schaedelin, Luisa M Villar, Jan D Lünemann, Jorge Correale, Jan Lycke

JAMA Neurol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activity.
Sarah Lindberg, Sofia Sandgren, Markus Axelsson, Igal Rosenstein, Jan Lycke

Mult Scler· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain-Derived Tau as an Outcome Marker in Guillain-Barré Syndrome: A Retrospective Cohort Study.
Brynhildur Hafsteinsdóttir, Fernando Gonzalez-Ortiz, Nina Gleisner, Ellen Alpsten, Jan Lycke

Eur J Neurol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.
Manuel Comabella, Harald Hegen, Luisa M Villar, Konrad Rejdak, Augusto Sao-Avilés, Jan Lycke

J Neurol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyro3 and Gas6 are associated with white matter and myelin integrity in multiple sclerosis.
Igal Rosenstein, Lenka Novakova, Hlin Kvartsberg, Anna Nordin, Sofia Rasch, Jan Lycke

J Neuroinflammation· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.
Antonio Scalfari, Anthony Traboulsee, Jiwon Oh, Laura Airas, Stefan Bittner, Jan Lycke

Ann Neurol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barré syndrome.
Brynhildur Hafsteinsdóttir, Helen Farman, Nina Lagerström, Henrik Zetterberg, Oluf Andersen, Jan Lycke

J Neurol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center study.
Sofia Sandgren, Lenka Novakova, Anna Nordin, Hemin Sabir, Markus Axelsson, Jan Lycke

Mult Scler Relat Disord· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using serum neurofilament-light in clinical practice: Growing enthusiasm that may need bridling.
Jan Lycke, Robert J Fox

Mult Scler· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
Fredrik Piehl, Peter Alping, Suvi Virtanen, Simon Englund, Joachim Burman, Jan Lycke

Ann Neurol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgG and kappa free light chain CSF/serum indices: evaluating intrathecal immunoglobulin production in HIV infection in comparison with multiple sclerosis.
Lars Hagberg, Igal Rosenstein, Jan Lycke, Henrik Zetterberg, Aylin Yilmaz

Clin Chem Lab Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study.
Susanna Hallberg, Björn Evertsson, Ellen Lillvall, Malin Boremalm, Pierre de Flon, Jan Lycke

Eur J Neurol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
Jan D Lunemann, Harald Hegen, Luisa María Villar, Konrad Rejdak, Augusto Sao-Aviles, Jan N Lycke

Neurol Neuroimmunol Neuroinflamm· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab treatment in pediatric-onset multiple sclerosis.
Markus Breu, Fredrik Sandesjö, Ruxandra-Iulia Milos, Jan Svoboda, Jonatan Salzer, Jan Lycke

Eur J Neurol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
Nicolás Fissolo, Pascal Benkert, Jaume Sastre-Garriga, Neus Mongay-Ochoa, Andreu Vilaseca-Jolonch, Jan Lycke

J Neurol Neurosurg Psychiatry· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management.
Mark S Freedman, Sharmilee Gnanapavan, Ronald A Booth, Peter A Calabresi, Michael Khalil, Jan Lycke

EBioMedicine· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medically unexplained symptoms are common in women in tertiary neurological healthcare center: A survey cohort study of persons investigated for suspected multiple sclerosis.
Lenka Novakova, Anna Karin Hedström, Markus Axelsson, Anne Frandsen Brandt, Lars Alfredsson, Jan Lycke

Brain Behav· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
Simone Hjæresen, Eirikur Benedikz, Tobias Sejbaek, Markus Axelsson, Lenka Novakova, Jan Lycke

J Neurol Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.
Thomas Silfverberg, Christina Zjukovskaja, Per Ljungman, Adjmal Nahimi, Erik Ahlstrand, Jan Lycke

J Neurol Neurosurg Psychiatry· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis.
Sofia Sandgren, Lenka Novakova, Anna Nordin, Markus Axelsson, Clas Malmeström, Jan Lycke

Front Neurol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis